Daiichi Sankyo to Lead Open Innovation Research on Cell Therapy

By • on January 14, 2019

The BioSpectrumAsia website reported that Daiichi Sankyo Company, Mitsubishi UFJ Capital Co.,  and Tokyo Institute of Technology have announced that they will commence open innovation research with the aim of creating insulin producing cells from iPS cells for use in regenerative medicine and cell therapy. The research is the 4th OiDE Fund investment, and Daiichi Sankyo and Mitsubishi UFJ Capital plan to continue to carry out further open innovation projects to develop new drug discovery platform technologies using the OiDE fund.

Click here to read the full article.

Image via Flickr.

Related Posts

Related Entries

Recent Entries

Purchase viagra online and purchase it from the good to cope with dependable and trustworthy pharmacy. Don't believe of the recommendation by a mantra but instead as suggestion that is useful since that might be really a correct move to make to think about. It's not just about general ease of doing all of your buying resting before your Computer, or around no prerequisite to depart your home or stand-in point, but additionally concerning the choices you might have barely considered overall. Visit the drugstore you might have handled earlier in the event that you know the thing you need precisely. Examine the options what, why and just how if, nevertheless, you will find neither particular needs or a drugstore to go to.